Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Theralase Hiring New IR Coordinator
View:
Post by Eoganacht on May 06, 2022 12:07pm

Theralase Hiring New IR Coordinator

Looks like Theralase is going to go back to responding to enquiries from shareholders and issuing quarterly newsletters.

Public Relations - Investor Relations Coordinator

Theralase Technologies Inc.
Public Relations - Investor Relations Coordinator
Toronto
Employer est.:$80K - $100K 
 
Overview:
 
Theralase® Technologies Inc. (“Theralase®”) is a publicly traded Canadian federal corporation (TSXV: TLT; OTCQB: TLTFF), which consists of two primary divisions:
 
1) Anti-Cancer Therapy (“ACT”) division, which is a clinical stage, pre-commercialization research and development division dedicated to the research and development of Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers, bacteria and viruses, when light activated by proprietary medical laser systems.
 
2) Cool Laser Therapy (“CLT”) division, which is a commercial division that designs, manufactures and distributes proprietary super-pulsed CLT medical lasers, primarily in Canada and the United States, for the treatment of knee pain, and in off-label use, treatment of numerous nerve, muscle and joint conditions. The CLT division also designs and manufactures proprietary medical laser systems used to activate the PDCs in the ACT division.
 
Additional information is available at www.theralase.com and www.sedar.com
 
Description:
 
The Public Relations - Investor Relations Coordinator (“PR-IR Coordinator”) will possess a minimum of 5 years of in-depth experience being the public face of a company in public relations and in addressing investor inquiries in investor relations.
 
The PR-IR Coordinator will be responsible for researching, organizing, compiling and presenting effective scripts and power point presentations that clearly and concisely communicate the accomplishments, opportunities, value proposition, near-term and long-term objectives of the Company to various stakeholders.
 
Stakeholders include:
 
· Current shareholders
 
· Potential shareholders
 
· Investment banks
 
· Biotech analysts
 
· Retail investors and family offices
 
· Institutional investors and fund managers
 
· Communication organizations (i.e.: print, radio, digital)
 
· Local, provincial and federal government organizations
 
· Various digital marketing channels
 
The strategic objective of the PR-IR Coordinator will be to achieve the Company’s Key Performance Indicators (“KPIs”) by delivering effective, clear, concise communications to Company stakeholders through scripts and power point presentations to inform them about the Company and commit them to action.
 
KPIs include: Corporate image, financings, daily trading volume and common stock price.
 
With a strong organizational and analytical focus, the PR-IR Coordinator will research, compile, and update monthly, a 12 month rolling calendar of events and campaigns, to be presented to senior management for final approval, intended to communicate the Company’s accomplishments, opportunities, value proposition and near-term objectives to stakeholders with a focus on achieving the KPIs.
 
Prior to execution of each event or campaign, the PR-IR Coordinator will estimate the expected increase in KPIs and after completion record the actual increase in KPIs achieved, with a focus on analyzing and optimizing what events or campaigns were successful, which were unsuccessful and what improvements could be made to achieve KPIs.
 
The PR-IR Coordinator’s excellent written, oral and presentation skills, in the English language, and drive to succeed will allow them to excel in this position and consistently achieve their strategic objectives.
 
Duties and Responsibilities:
 
· Achieve and/or surpass KPIs
 
· Overall management of all stakeholder initiatives; including: scheduling and budget, subject to senior manager approval
 
· Effective media relations to achieve the Company’s KPIs
 
· Professionally and succinctly address inbound queries from: investors, the press, media and other organizations by providing only publicly released material information, in compliance with continuous disclosure and insider information rules and regulations
 
· Speaking publicly at interviews, press conferences and presentations
 
· Prospect for new stakeholders for the Company
 
· Place outbound stakeholder calls to schedule verbal, in-person or digital attendance at stakeholder meetings or events to update them on the Company’s accomplishments, opportunities, value proposition, near-term and long-term objectives
 
· Document contact information and daily interactions with stakeholders via a Customer Relationship Management (“CRM”) cloud-based program
 
· Research and compile financial valuations of the Company to create financial models to support a view on the Company’s share price
 
· Research, organize, compile and present effective scripts and power point presentations
 
· Research, compile, and update monthly, a 12 month rolling calendar of events and campaigns, subject to senior management approval
 
· Prior to execution of each event or campaign, estimate the expected increase in KPIs and after completion record the actual increase in KPIs achieved, with a focus on analyzing and optimizing
 
· In conjunction with the finance department, research, compile and write effective press releases and quarterly newsletters on material corporate matters and obtain written authorization from pertinent stakeholders, senior management and the corporate disclosure committee to publicly release
 
· Send approved press releases and quarterly newsletters to newswire services for SEDAR and media release
 
· E-mail an executive summary and the press release to the stakeholder CRM database
 
· Compile script and coordinate with the marketing department to video the PR-IR Coordinator speaking about various subjects to be released via social media, embedded in press releases and/or added to the corporate website
 
· Review corporate website for clarity, accuracy and navigation of stakeholder information and provide new optimized stakeholder material to the marketing department web designer for update of the corporate website
 
· Organize Annual General Meeting (“AGM”) in conjunction with the finance department and corporate transfer agent
 
· Update social media with the latest approved stakeholder information
 
· Research and create internal intelligence reports on similar companies in the pharmaceutical and medical device industry to track performance and benchmark of the Company’s accomplishments, value proposition, common stock price and trading volume in relation to peers.
 
· Work in conjunction with the marketing team to compile all stakeholder assets required for each event (i.e.: power point presentation decks, pop up displays, stakeholder brochures, handouts, giveaways)
 
· Other duties as may be assigned during the course of employment
 
Skills and Qualifications Required:
 
· Bachelor of Arts degree in business communication or professional communication
 
· Minimum of 5 years of in-depth experience being the public face of a company in public relations and in addressing investor inquiries in investor relations
 
· Work experience in the biotechnical or pharmaceutical industry, an asset
 
· Extroverted, skilled in effective communications ranging from one-on-one meetings to large group presentations
 
Completed formal media training
Creative in design of communication materials
Extremely strong command of the English language with an ability to research, compose and publish well-written documents and power point presentations delivering compelling arguments directed to a wide variety of audiences
Excellent oral, written and presentation communication skills, in the English language
Advanced competency in Microsoft Office environment (i.e.: Office, Excel, Outlook, Word, Power Point, Publisher)
· Able to produce work of very high quality with minimum to no grammar or spelling mistakes
 
· Able to travel to the USA and within Canada for 2 to 5 day pre-arranged business trips, as required
 
Proven ability to achieve strategic objectives and KPIs
Self-disciplined, self-motivated and professional in demeanor
Team player with a proven ability to build positive relationships at all levels of an organization and with various stakeholders
Polished individual who remains calm and focused under pressure
Deadline orientated with an ability to meet tight deadlines
Organized, with an ability toprioritize in a multi-tasking environment with excellent attention to detail and accuracy
Enjoys working in a challenging and fast growth environment
Demonstrated flexibility and adaptability with an ability to analyze past performance and implement strategies to improve future performance
Hard working, lead by example
Compensation:
 
$80,000 to $100,000 base, commensurate with experience
 
Performance bonus, employee benefits and stock options (subject to board of director’s approval)
 
Please send your resume for review and consideration.
 
Only candidates, who are being considered for the PR-IR Coordinator position will be contacted.
 
Job Type: Full-time
 
Salary: $80,000.00-$100,000.00 per year
 
Additional pay:
 
Bonus pay
Benefits:
 
Dental care
Extended health care
Vision care
Schedule:
 
Monday to Friday
COVID-19 considerations:
All employees are expected to wear a mask when not in their office or work station. The common areas (washrooms and kitchen) are cleaned and sanitized by an external cleaning company 3 times per week.
 
Education:
 
Bachelor's Degree (required)
Experience:
 
Public Relations - Investor Relations: 5 years (preferred)
Comment by Larrymartin77 on May 06, 2022 12:11pm
good info
Comment by Oilminerdeluxe on May 06, 2022 12:26pm
Nice. Finally.
Comment by Legit62 on May 06, 2022 2:22pm
I would take these hirings as a very positive sign, we are getting very close to a money stream IMO, whether partnering or getting our BTD and commercialization, great to see this
Comment by stocksnbonds458 on May 06, 2022 6:16pm
How in God's name can we be getting close to a revenue stream and commercialization when we haven't even received BTF, let alone FDA approval.
Comment by Vikingstock on May 06, 2022 7:23pm
Clearly a money stream and a revenue stream are different. We will most probable need money end of year or early next. Discussions with potential candidates or jv takes time, needs to start early outlining key points.
Comment by Legit62 on May 06, 2022 8:57pm
Clearly didnt mean revenue, obviously we are way away from any type of substantial revenue, i was thinking more of a partner coming on board with some financial support, i still believe we may see this before any BTD announced, and would bet we have been in talks all along with FDA, i would think Dr Vera has been highly involved in this
Comment by LaserStock29 on May 06, 2022 10:24pm
I think Endocyte had exaclty $0 dollars of revenue.. was exiting phase 2 into phase 3 before Novartis paid 2.1b for their 'single asset' radionucleotide molecule.  Im here for the big PPS run to $2 bucks+++ long before revenue even enters this conversation. Please dont say we are gonna sit at .30 cents until we're making revenue on TLD-1433  lol
Comment by Rumpl3StiltSkin on May 06, 2022 10:56pm
I agree, There is this thing called FOMO. If it looks like a deal is in the works, based on improving CR data or Covid data, that info will leak and SP will move up. BIG!!
Comment by Yajne on May 06, 2022 11:14pm
Totally agree with all points on this thread that suggest some sort of deal before BTD. Rumpl3, I personally consider the whole Covid thing a 'distraction'. Hope I'm proved wrong, Their ACT is what I'm here for and IMO what most longs are here for.
Comment by Oilminerdeluxe on May 07, 2022 11:23am
Just a thought. We all want a nice value creating deal and all that. However, since this is Roger's baby, is it not probable that such a deal will not come until after his return as CEO? If that is the plan that is. I might be waaay wrong. First BTD, then Roger returns, then Ka-Boom! It sounds so easy. :-)
Comment by Infinity on May 07, 2022 2:42pm
Legit62. I agree. We are heading in the right direction with Manager for Engineering to beef up the manufacturing process, improve quality control... Not so sure about the co-ordinator for Investor relations. Would have preferred a PR company that specialises in small cap Biotech stocks at this stage instead of increasing the over heads. I believe TLT management is gearing up for a major shift in ...more  
Comment by Gooseybear on May 08, 2022 9:09pm
Their investor relations has been terrible over the years so agree that they need someone specialized in biotechs.
Comment by Rumpl3StiltSkin on May 09, 2022 11:13am
  If they did this it would be great. Past choices weren't so good IMO. I think with improving numbers and a possible universal Covid vax/treatment, this persons job would be easy.
Comment by Gooseybear on May 09, 2022 11:22am
The IR person I dealt with sounded like someone just out of college with little knowledge of the business. She's no longer there.
Comment by ScienceFirst on May 09, 2022 11:50am
No matter who's hired, they won't be able to say more than what's public.  So some should lower their expectations.   Clinical data is what will move this stock.  The MD&A and corporate presentation give us enough additional and perspectives to know the direction where we're heading (NMIBC, COVID-19, NSCLC).  The rest is about execution, with priority #1 ...more  
Comment by 99942Apophis on May 09, 2022 12:06pm
Absolutely agree ScienceFirst on all accounts.
Comment by Oilminerdeluxe on May 09, 2022 12:15pm
It would be wonderful indeed.
Comment by patience69 on May 09, 2022 2:03pm
Science. I am with you 100%. This is exactly what I see too. The moving of BTD was likely a business decision & BTD will be accomplished as we transition to a new entitiy with a partner. My only question remains when will this become in the public domain? If a conditional deal gets agreed to & signed is that not news? Maybe the AGM would be a good time for such a presentation?
Comment by BlueFranky on May 09, 2022 2:41pm
Funny thing patience - I raised that same scenario//question with a friend just a week ago
Comment by 99942Apophis on May 09, 2022 2:59pm
I believe a material news of that nature has a 10 day allowance to be made public by the Security Commission. If this is incorrect would someone post the accurate time allowance. 
Comment by Rumpl3StiltSkin on May 09, 2022 3:11pm
Pop, Skys is right. IF TLT knows they will get a substantial grant from LKSKI, based on good CR data, etc. Then no need for a deal even. Right? Therefore no material news until the grant goes thru.
Comment by patience69 on May 09, 2022 3:30pm
You guys are probably going to think that I am nuts but what if LKSKI was the partner for China. Someone else say Merck or Roche or whoever for North America? Either way we will be all set soon
Comment by Rumpl3StiltSkin on May 09, 2022 3:45pm
I don't think LKS is pro-China, or more corectly, pro CCP. Yet he is a business man...
Comment by 99942Apophis on May 09, 2022 5:08pm
Rumpl3StiltSkin wrote  Pop, Skys is right. IF TLT knows they will get a substantial grant from LKSKI, based on good CR data, etc. Then no need for a deal even. Right? Therefore no material news until the grant goes thru. Hi Rumpl3StiltSkin "knowing they will get anything doesn't make it material news" but as Skys says when they get either a grant or an agreement of one or more ...more  
Comment by Rumpl3StiltSkin on May 09, 2022 2:55pm
  Interesting discussion and Great Question?? Also, would explain the cancelation of the shelf prospectus shares last year.
Comment by BlueFranky on May 09, 2022 2:59pm
Good point rumpl3!
Comment by patience69 on May 09, 2022 3:01pm
Blue & Rump Look how much it explains!!  Prospectus (lack of $$ concerns). No search for CEO (will likely be Roger). Location at Li  Ka Shing for research. Starting new indications end of year too  It really explains about everything
Comment by skys1 on May 09, 2022 3:04pm
Like I have been saying for a year now, there is no way Li Ka Shing et al would have given a brand new, first class, fully equiped bio research lab to TLT on their premises just because they think the folks at TLT are nice guys. There has to be more to it than that, especially since it's on St Mike's premises. Anything that happens in that lab, Li Ka Shing will know about it first.
Comment by skys1 on May 09, 2022 3:34pm
Yes, there is no signed deal in place, however I believe Li Ka Shing is hoping in that direction with the gift of the new bio lab, plus they have already referred to TLT as, "partner". When TLT gets the needed approvals to commercialize their ACT which should be close to year end, they sign a deal and Li Ka Shing puts their worldwide pharma wheels in motion. This also explains why TLT no ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250